Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

100.04 -0.85 (-0.84%)
Streaming Delayed Price Updated: 11:56 AM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
News headline image
Merck Announces Positive Data From Trials For Cholesterol Drug, But Retail Reaction Is Sluggish ↗
Dean Y. Li, president of Merck Research Laboratories, said that the company is working with urgency to make the oral therapy available to patients worldwide. 
Via Stocktwits
News headline image
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
Top S&P500 movers in Monday's pre-market session ↗
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia
From Merck & Co., Inc.
Via Business Wire
News headline image
Unpacking the Latest Options Trading Trends in Merck & Co ↗
 
Via Benzinga
News headline image
How Do Investors Really Feel About Merck & Co? ↗
 
Via Benzinga
News headline image
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗
Each of the index's highest-yielding names has its own unique story right now. 
Via The Motley Fool
Topics Economy Stocks
News headline image
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta ↗
Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates. 
Via Benzinga
Topics Bankruptcy
News headline image
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug ↗
Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives. 
Via Benzinga
News headline image
9 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully
From HKTDC
Via ACN Newswire
News headline image
Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
News headline image
1 Value Stock to Target This Week and 2 to Question
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
News headline image
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover ↗
The deal is being discussed ahead of key data from MoonLake in patients with a skin disease. 
Via Investor's Business Daily
News headline image
Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report ↗
Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff. 
Via Benzinga
Topics Intellectual Property
News headline image
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers ↗
Merck shared safety and efficacy results of MK-1084; either as monotherapy or in combinations, it demonstrated a manageable safety profile. 
Via Benzinga
News headline image
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure ↗
There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival. 
Via Investor's Business Daily
News headline image
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial
From Merck & Co., Inc.
Via Business Wire
News headline image
2 Cash-Producing Stocks for Long-Term Investors and 1 to Steer Clear Of
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
Merck, Daiichi Sankyo Pull FDA Application For Lung Cancer Therapy: Retail Terms It A ‘Huge Flop’ ↗
The decision is based on results from a late-stage trial in which the drug failed to prolong patients' lives, the companies stated. 
Via Stocktwits
News headline image
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% ↗
Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review. 
Via Benzinga
News headline image
Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn
From Daiichi Sankyo
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Merck Announces Third-Quarter 2025 Dividend
From Merck & Co., Inc.
Via Business Wire
News headline image
MERCK & CO. INC. (NYSE:MRK) - A Reliable Dividend Stock with Strong Fundamentals ↗
MERCK & CO. (NYSE:MRK) offers a strong 4.2% dividend yield, consistent growth, and solid financial health, making it a top pick for dividend investors. 
Via Chartmill
News headline image
"If Walmart Is Under Pressure to Raise Prices, It's Going to Have Broader Effects on the Economy." ↗
Via The Motley Fool
Topics Earnings Economy World Trade
News headline image
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics ↗
The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge. 
Via Investor's Business Daily
News headline image
3 Dow Jones Stocks on Our Watchlist
The Dow Jones (^DJI) includes some of the most reliable stocks in the market, and while not all are equal, a few continue to shine. These companies are leveraging their strengths to maintain leadership... 
Via StockStory
Topics Stocks
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.